Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Clinical Study to Evaluate the Efficacy and Safety of SI-B001 Combined With Irinotecan in the Treatment of Recurrent and Metastatic Esophageal Squamous Cell Carcinoma

NCT05022654 is registered in ClinicalTrials.gov with Sichuan Baili Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT05022654
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05022654 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Clinical Study to Evaluate the Efficacy and Safety of SI-B001 Combined With Irinotecan in the Treatment of Recurrent and Metastatic Esophageal Squamous Cell Carcinoma
Lead sponsor
Sichuan Baili Pharmaceutical Co., Ltd.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
December 13, 2021
Completion date
December 31, 2025
Enrollment
22 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

esophageal squamous cell carcinomas